Search Results - "Zahlten-Kümeli, Anita" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Bemarituzumab plus mFOLFOX6 as first-line treatment in East Asian patients with FGFR2b-overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer: subgroup of FIGHT final analysis

Bemarituzumab plus mFOLFOX6 as first-line treatment in East Asian patients with FGFR2b-overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer: subgroup of FIGHT final analysis

by Kang, Yoon-Koo, Qin, Shukui, Lee, Keun-Wook, Oh, Sang Cheul, Kim, In-Ho, Kim, Jong Gwang, Li, Yong, Yan, Zhuchen, Li, Jin, Bai, Li-Yuan, Chan, Catherine, Yusuf, Akeem, Zahlten-Kümeli, Anita, Taylor, Kate, Yamaguchi, Kensei
Published in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (01.09.2024)

Get full text

Journal Article

Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial

Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial

by Wainberg, Zev A., Kang, Yoon-Koo, Lee, Keun-Wook, Qin, Shukui, Yamaguchi, Kensei, Kim, In-Ho, Saeed, Anwaar, Oh, Sang Cheul, Li, Jin, Turk, Haci Mehmet, Teixeira, Alexandra, Hitre, Erika, Udrea, Adrian A., Cardellino, Giovanni Gerardo, Sanchez, Raquel Guardeño, Zahlten-Kümeli, Anita, Taylor, Kate, Enzinger, Peter C.
Published in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (01.05.2024)

Get full text

Journal Article

$Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy$

Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy

by Quach, Hang, Nooka, Ajay, Samoylova, Olga, Venner, Christopher P., Kim, Kihyun, Facon, Thierry, Spencer, Andrew, Usmani, Saad Z., Grosicki, Sebastian, Suzuki, Kenshi, Delimpasi, Sosana, Weisel, Katja, Obreja, Mihaela, Zahlten‐Kumeli, Anita, Mateos, Maria‐Victoria
Published in British journal of haematology (01.08.2021)

Get full text

Journal Article

Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m2 vs. twice-weekly 27 mg/m2 carfilzomib (randomized A.R.R.O.W. study)

Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m2 vs. twice-weekly 27 mg/m2 carfilzomib (randomized A.R.R.O.W. study)

by Moreau, Philippe, Kumar, Shaji, Boccia, Ralph, Iida, Shinsuke, Goldschmidt, Hartmut, Cocks, Kim, Trigg, Andrew, Zahlten-Kumeli, Anita, Yucel, Emre, Panjabi, Sumeet S., Dimopoulos, Meletios
Published in Leukemia (01.12.2019)

Get full text

Journal Article

$Once‐weekly (70 mg/m2) vs twice‐weekly (56 mg/m2) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION‐1 trials$

Once‐weekly (70 mg/m2) vs twice‐weekly (56 mg/m2) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION‐1 trials

by Moreau, Philippe, Stewart, Keith A., Dimopoulos, Meletios, Siegel, David, Facon, Thierry, Berenson, James, Raje, Noopur, Berdeja, Jesus G., Orlowski, Robert Z., Yang, Hui, Ma, Haijun, Klippel, Zandra, Zahlten‐Kumeli, Anita, Mezzi, Khalid, Iskander, Karim, Mateos, Maria‐Victoria
Published in Cancer medicine (Malden, MA) (01.05.2020)

Get full text

Journal Article

Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials

Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials

by Dimopoulos, Meletios A., Moreau, Philippe, Iida, Shinsuke, Huang, Shang-Yi, Takezako, Naoki, Chng, Wee Joo, Zahlten-Kumeli, Anita, Sersch, Martina A., Li, Julia, Huang, Mei, Lee, Jae Hoon
Published in International journal of hematology (01.10.2019)

Get full text

Journal Article

Carfilzomib as salvage therapy in Waldenstrom macroglobulinemia: a case series

Carfilzomib as salvage therapy in Waldenstrom macroglobulinemia: a case series

by Vesole, David H., Richter, Joshua, Biran, Noa, McBride, Laura, Anand, Palka, Huang, Mei, Kumeli, Anita-Zahlten, Klippel, Zandra, Iskander, Karim, Siegel, David S.
Published in Leukemia & lymphoma (02.01.2018)

Get full text

Journal Article

$Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis$

Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis

by Dimopoulos, Meletios A., Niesvizky, Ruben, Weisel, Katja, Siegel, David S., Hajek, Roman, Mateos, María-Victoria, Cavo, Michele, Huang, Mei, Zahlten-Kumeli, Anita, Moreau, Philippe
Published in Blood cancer journal (New York) (09.03.2020)

Get full text

Journal Article

$Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study$

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study

by Dimopoulos, Meletios, Quach, Hang, Mateos, Maria-Victoria, Landgren, Ola, Leleu, Xavier, Siegel, David, Weisel, Katja, Yang, Hui, Klippel, Zandra, Zahlten-Kumeli, Anita, Usmani, Saad Z
Published in The Lancet (British edition) (18.07.2020)

Get full text

Journal Article

$Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial$

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial

by Dimopoulos, Meletios A, Goldschmidt, Hartmut, Niesvizky, Ruben, Joshua, Douglas, Chng, Wee-Joo, Oriol, Albert, Orlowski, Robert Z, Ludwig, Heinz, Facon, Thierry, Hajek, Roman, Weisel, Katja, Hungria, Vania, Minuk, Leonard, Feng, Shibao, Zahlten-Kumeli, Anita, Kimball, Amy S, Moreau, Philippe
Published in The lancet oncology (01.10.2017)

Get full text

Journal Article

Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma

Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma

by Facon, Thierry, Lee, Jae Hoon, Moreau, Philippe, Niesvizky, Ruben, Dimopoulos, Meletios, Hajek, Roman, Pour, Ludek, Jurczyszyn, Artur, Qiu, Lugui, Klippel, Zandra, Zahlten-Kumeli, Anita, Osman, Muhtarjan, Paiva, Bruno, San-Miguel, Jesus
Published in Blood (02.05.2019)

Get full text

Journal Article

$Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study$

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study

by Usmani, Saad Z, Quach, Hang, Mateos, Maria-Victoria, Landgren, Ola, Leleu, Xavier, Siegel, David, Weisel, Katja, Gavriatopoulou, Maria, Oriol, Albert, Rabin, Neil, Nooka, Ajay, Qi, Ming, Beksac, Meral, Jakubowiak, Andrzej, Ding, Bifeng, Zahlten-Kumeli, Anita, Yusuf, Akeem, Dimopoulos, Meletios
Published in The lancet oncology (01.01.2022)

Get full text

Journal Article

$Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study$

Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study

by Moreau, Philippe, Mateos, Maria-Victoria, Berenson, James R, Weisel, Katja, Lazzaro, Antonio, Song, Kevin, Dimopoulos, Meletios A, Huang, Mei, Zahlten-Kumeli, Anita, Stewart, A Keith
Published in The lancet oncology (01.07.2018)

Get full text

Journal Article

Trial in progress: Phase 3 study of bemarituzumab + mFOLFOX6 versus placebo + mFOLFOX6 in previously untreated advanced gastric or gastroesophageal junction (GEJ) cancer with FGFR2b overexpression (FORTITUDE-101)

Trial in progress: Phase 3 study of bemarituzumab + mFOLFOX6 versus placebo + mFOLFOX6 in previously untreated advanced gastric or gastroesophageal junction (GEJ) cancer with FGFR2b overexpression (FORTITUDE-101)

by Smyth, Elizabeth Catherine, Chao, Joseph, Muro, Kei, Yen, Priscilla, Yanes, Rolando Eduardo, Zahlten-Kumeli, Anita, Rha, Sun Young
Published in Journal of clinical oncology (01.06.2022)

Get full text

Journal Article

$Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma$

Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma

by Siegel, David, Weisel, Katja, Zahlten-Kumeli, Anita, Medhekar, Rohan, Ding, Bifeng, Leleu, Xavier
Published in Leukemia & lymphoma (15.10.2021)

Get full text

Journal Article

$Health related quality of life (HRQoL) outcomes from the phase III CANDOR study comparing carfilzomib, dexamethasone, and daratumumab (KdD) to carfilzomib and dexamethasone (Kd) in patients (Pts) with relapsed or refractory multiple myeloma$

Health related quality of life (HRQoL) outcomes from the phase III CANDOR study comparing carfilzomib, dexamethasone, and daratumumab (KdD) to carfilzomib and dexamethasone (Kd) in patients (Pts) with relapsed or refractory multiple myeloma

by Siegel, David Samuel DiCapua, Weisel, Katja, Zahlten-Kumeli, Anita, Medhekar, Rohan, Sapra, Sandhya, Ding, Bifeng, Leleu, Xavier
Published in Journal of clinical oncology (20.05.2020)

Get full text

Journal Article

$Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy and Safety Results of the Phase 3 Candor Study$

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy and Safety Results of the Phase 3 Candor Study

by Dimopoulos, Meletios A, Quach, Hang, Mateos, María-Victoria, Landgren, Ola, Leleu, Xavier, Siegel, David S., Weisel, Katja, Gavriatopoulou, Maria, Oriol, Albert, Rabin, Neil K, Nooka, Ajay, Qi, Ming, Ding, Bifeng, Zahlten-Kumeli, Anita, Usmani, Saad Z.
Published in Blood (05.11.2020)

Get full text

Journal Article

$Efficacy and Safety of Carfilzomib and Dexamethasone in Lenalidomide Exposed and Refractory Multiple Myeloma Patients: Combined Analysis of Carfilzomib Trials$

Efficacy and Safety of Carfilzomib and Dexamethasone in Lenalidomide Exposed and Refractory Multiple Myeloma Patients: Combined Analysis of Carfilzomib Trials

by Mateos, Maria-Victoria, Berdeja, Jesus G., Dimopoulos, Meletios A, Siegel, David S, Ho, P Joy, Huang, Mei, Sersch, Martina, Zahlten-Kumeli, Anita, Kimball, Amy S, Weisel, Katja
Published in Blood (29.11.2018)

Get full text

Journal Article

$Once Weekly Versus Twice Weekly Carfilzomib Dosing in Patients with Relapsed and Refractory Multiple Myeloma (A.R.R.O.W.): Efficacy and Safety Analyzed By Age Group$

Once Weekly Versus Twice Weekly Carfilzomib Dosing in Patients with Relapsed and Refractory Multiple Myeloma (A.R.R.O.W.): Efficacy and Safety Analyzed By Age Group

by Dimopoulos, Meletios A, Niesvizky, Ruben, Moreau, Philippe, Siegel, David S, Hajek, Roman, Mateos, Maria-Victoria, Cavo, Michele, Huang, Mei, Zahlten-Kumeli, Anita, Weisel, Katja
Published in Blood (29.11.2018)

Get full text

Journal Article

Efficacy and Safety of Once-Weekly vs Twice-Weekly Carfilzomib Plus Dexamethasone: Subgroup Analysis of the Phase 3 A.R.R.O.W. Study (NCT02412878) By Prior Lines

Efficacy and Safety of Once-Weekly vs Twice-Weekly Carfilzomib Plus Dexamethasone: Subgroup Analysis of the Phase 3 A.R.R.O.W. Study (NCT02412878) By Prior Lines

by Moreau, Philippe, Stewart, A Keith, Lazzaro, Antonio, Dimopoulos, Meletios A, Cavo, Michele, Ailawadhi, Sikander, Iskander, Karim, Huang, Mei, Zahlten-Kumeli, Anita, Mateos, Maria-Victoria
Published in Blood (29.11.2018)

Get full text

Journal Article